Predictive Oncology Inc. (POAI)
Market Cap | 13.21M |
Revenue (ttm) | 1.55M |
Net Income (ttm) | -19.32M |
Shares Out | 4.03M |
EPS (ttm) | -4.84 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 6,625 |
Open | 3.13 |
Previous Close | 3.16 |
Day's Range | 3.13 - 3.29 |
52-Week Range | 2.47 - 13.88 |
Beta | 1.52 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Nov 9, 2023 |
About POAI
Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomi... [Read more]
Financial Performance
In 2022, POAI's revenue was $1.51 million, an increase of 5.97% compared to the previous year's $1.42 million. Losses were -$25.74 million, 30.9% more than in 2021.
Financial StatementsNews

Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update
Company to host investor call and webcast today, August 10th, at 5:30pm EDT Company to host investor call and webcast today, August 10th, at 5:30pm EDT

Predictive Oncology to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on Thursday, August 10, 2023
EAGAN, Minn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, ...

Predictive Oncology Announces Relocation of Corporate Headquarters to Pittsburgh
Surrounded by world renowned universities and medical centers, Predictive Oncology is part of the next generation of Pittsburgh's innovation ecosystem

Predictive Oncology Appoints Biopharmaceutical Finance Veteran Mr. Andrew Einhorn to its Business Advisory Board
EAGAN, Minn., June 27, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, ...

Predictive Oncology Appoints Dr. Bernard A. Harris, Jr. to its Newly Formed Business Advisory Board
EAGAN, Minn., June 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, ...

Predictive Oncology invited to present groundbreaking approach to drug discovery at the 2023 BIO International Convention
Pamela Bush, Chief Business Officer of Predictive Oncology, to discuss advancing pipelines and using patient heterogeneity with AI to solve the missing link in drug discovery Pamela Bush, Chief Busine...

Predictive Oncology Reports First Quarter 2023 Financial Results and Provides Business Update
Company to host investor call and webcast today, May 15th, at 5:30pm EDT Company to host investor call and webcast today, May 15th, at 5:30pm EDT

Predictive Oncology Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on April 24, 2023 EAGAN, Minn., April 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Compan...

Predictive Oncology Adjourns Special Meeting of Stockholders
MINNEAPOLIS, April 17, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, exten...

Predictive Oncology Announces Appointment of Oncology Translational Research Leader Christoph Reinhard, Ph.D., MBA, to its Scientific Advisory Board
EAGAN, Minn., April 04, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities,...

Predictive Oncology Announces Collaboration with Integra Therapeutics to Advance Gene Therapy
EAGAN, Minn., March 30, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a science-driven company on the leading edge of oncology drug discovery and development, today announces it is part...

Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update
EAGAN, Minn., March 21, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities,...

Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs
EAGAN, Minn., March 17, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) together with Cancer Research Horizons, the innovation engine at the core of the world's largest private funder...

Predictive Oncology Announces Distribution of Series F Preferred Stock to Holders of its Common Stock
EAGAN, Minn., March 16, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that its Board of Directors declared a dividend of on...

Predictive Oncology Engages LifeSci Advisors as Strategic Investor Relations Partner
Comprehensive, multi-faceted IR program to focus on raising awareness of Predictive Oncology and its portfolio of unique, proprietary assets capable of accelerating oncologic drug discovery and enabli...

Predictive Oncology Issues Letter to Shareholders
EAGAN, Minn., March 09, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities to ac...

Predictive Oncology and Cvergenx announce partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence
EAGAN, Minn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) and Cvergenx, Inc. today announced an agreement to form a strategic partnership that has the potential to revolu...

Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer
EAGAN, Minn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead...

Pioneer of Computational Biology Joins the Scientific Advisory Board of Predictive Oncology
EAGAN, Minn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the appointment of Robert F. Murphy, Ph.D., to the company's Scientific Advisory Board where he ...

Distinguished Innovator in Genomics Joins the Scientific Advisory Board of Predictive Oncology
EAGAN, Minn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the appointment of Marc Malandro, Ph.D., to the company's Scientific Advisory Board where he wil...

Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D.
EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board...

Predictive Oncology Reports Third Quarter Financial Results
EAGAN, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its third quarter ended September 30, 2022, which continue to reflect ...

David S. Smith appointed to the Board of Directors of Predictive Oncology
Leading authority on the therapeutic use of human tissues and cells Leading authority on the therapeutic use of human tissues and cells

Predictive Oncology Announces New Chief Executive Officer Raymond F. Vennare to Lead Company Growth
EAGAN, Minn., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) is pleased to announce the appointment of Raymond F. Vennare as Chief Executive Officer and Chairman of the Board, ef...

Predictive Oncology Strengthens Offerings with GMP Lab and Addition of Leading Expert in Formulation Development
EAGAN, Minn., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced several key developments to further strengthen the company's offerings for pharmaceutical and biotec...